TWO COST-EFFECTIVENESS ANALYSES OF THE USE OF CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE VERSUS LENALIDOMIDE PLUS DEXAMETHASONE AND CARFILZOMIB PLUS DEXAMETHASONE VERSUS BORTEZOMIB PLUS DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN COLOMBIA

被引：0
|
作者：
van Beurden-Tan, C. [1 ]
Forero, J. [2 ]
Coggia, A. [1 ]
Bustos Marquez, M. C. [2 ]
机构：
[1] Amgen Inc, Rotkreuz, Switzerland
[2] Amgen Inc, Bogota, Colombia
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN225
引用
收藏
页码：S480 / S480
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Pollux Trial
    Maiese, Eric M.
    Graham, Christopher N.
    Hawe, Emma
    Le Moine, Jean-Gabriel
    Abraham, Ivo
    Senbetta, Mekre
    BLOOD, 2017, 130
  • [42] KRD (CARFILZOMIB PLUS LENALIDOMIDE PLUS DEXAMETHASONE) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A REAL LIFE SURVEY IN CAMPANIA REGION IN SOUTHERN ITALY
    Palmieri, S.
    Rocco, S.
    Migliaccio, I
    Cerchione, C.
    Catalano, L.
    Ferrara, K.
    Peluso, I
    Monaco, G.
    Farina, G.
    Gagliardi, A.
    Barone, M.
    Esposito, D.
    Amico, V
    Arcamone, M.
    Fontana, R.
    Sementa, A.
    Sica, A.
    Svanera, G.
    Pane, F.
    Ferrara, F.
    HAEMATOLOGICA, 2018, 103 : 36 - 37
  • [43] Isatuximab plus carfilzomib-dexamethasone for relapsed multiple myeloma
    Maruyama, Dai
    Yamauchi, Nobuhiko
    LANCET HAEMATOLOGY, 2024, 11 (10): : e710 - e711
  • [44] Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
    Shinsuke Iida
    Takaaki Chou
    Shinichiro Okamoto
    Hirokazu Nagai
    Kiyohiko Hatake
    Hirokazu Murakami
    Toshiyuki Takagi
    Kazuyuki Shimizu
    Henry Lau
    Kenichi Takeshita
    Masaaki Takatoku
    Tomomitsu Hotta
    International Journal of Hematology, 2010, 92 : 118 - 126
  • [45] Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
    Avet-Loiseau, Herve
    Casneuf, Tineke
    Chiu, Christopher
    Laubach, Jacob P.
    Lee, Je-Jung
    Moreau, Philippe
    Plesner, Torben
    Nahi, Hareth
    Khokhar, Nushmia Z.
    Qi, Ming
    Schecter, Jordan
    Carlton, Victoria
    Qin, Xiang
    Liu, Kevin
    Wu, Kaida
    Zhuang, Sen H.
    Ahmadi, Tahamtan
    Sasser, A. Kate
    San-Miguel, Jesus
    BLOOD, 2016, 128 (22)
  • [46] Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
    Spencer, Andrew
    Lentzsch, Suzanne
    Weisel, Katja
    Avet-Loiseau, Herve
    Mark, Tomer M.
    Spicka, Ivan
    Masszi, Tamas
    Lauri, Birgitta
    Levin, Mark-David
    Bosi, Alberto
    Hungria, Vania
    Cavo, Michele
    Lee, Je-Jung
    Nooka, Ajay K.
    Quach, Hang
    Lee, Cindy
    Barreto, Wolney
    Corradini, Paolo
    Min, Chang-Ki
    Scott, Emma C.
    Chanan-Khan, Asher A.
    Horvath, Noemi
    Capra, Marcelo
    Beksac, Meral
    Ovilla, Roberto
    Jo, Jae-Cheol
    Shin, Ho-Jin
    Sonneveld, Pieter
    Soong, David
    Casneuf, Tineke
    Chiu, Christopher
    Amin, Himal
    Qi, Ming
    Thiyagarajah, Piruntha
    Sasser, A. Kate
    Schecter, Jordan M.
    Mateos, Maria-Victoria
    HAEMATOLOGICA, 2018, 103 (12) : 2079 - 2087
  • [47] Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma.
    Maiese, Eric
    Graham, Christopher N.
    Hawe, Emma
    Le Moine, Jean-Gabriel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma
    Narsipur, Nihal
    Bulla, Sabrina
    Yoo, Connie
    Do, Brenda
    Tran, Kyle
    Gu, Dian
    Zhong, Lixian
    Wilson, Leslie
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (12) : 1691 - 1702
  • [49] Lenalidomide plus dexamethasone is effective in multiple myeloma
    Meijer, Ellen
    Sonneveld, Pieter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (05) : 247 - 248
  • [50] Lenalidomide plus dexamethasone is effective in multiple myeloma
    Ellen Meijer
    Pieter Sonneveld
    Nature Reviews Clinical Oncology, 2009, 6 : 247 - 248
12345